Cargando…
Neoadjuvant chemoradiation therapy combined with immunotherapy for microsatellite stable ultra-low rectal cancer (CHOICE II): study protocol of a multicentre prospective randomised clinical trial
INTRODUCTION: Neoadjuvant chemoradiotherapy (nCRT) could bring tumour shrinking and downstaging and increase the probability of organ preservation for patients with low rectal cancer. But for ultra-low rectal cancer, there is little possibility for organ preservation. Immunotherapy has been shown to...
Autores principales: | Zhou, Leqi, Yu, Guanyu, Wen, Rongbo, Jia, Hang, Zhang, Tianshuai, Peng, Zhiying, Fan, Hao, Pan, Anfu, Yu, Yue, Zhu, Xiaoming, Gong, Haifeng, Gao, Xianhua, Lou, Zheng, Zhang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503376/ https://www.ncbi.nlm.nih.gov/pubmed/37709314 http://dx.doi.org/10.1136/bmjopen-2022-069793 |
Ejemplares similares
-
Single-cell sequencing technology in colorectal cancer: a new technology to disclose the tumor heterogeneity and target precise treatment
por: Wen, Rongbo, et al.
Publicado: (2023) -
Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment
por: Suwanthanma, Weerapat, et al.
Publicado: (2021) -
Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer
por: Ferrari, Linda, et al.
Publicado: (2015) -
Neoadjuvant chemoradiation for rectal cancer in patients aged 75 years or older
por: Lombardi, Raffaele, et al.
Publicado: (2009) -
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer
por: Restivo, Angelo, et al.
Publicado: (2015)